Summary: CollPlant Biotechnologies and Stratasys Ltd. have initiated a pre-clinical study to develop 3D-printed regenerative breast implants that promote natural tissue growth and biodegrade over time.
Key Takeaways
- Innovative Collaboration: CollPlant Biotechnologies and Stratasys Ltd. are collaborating to develop 3D-printed regenerative breast implants using CollPlant’s bioinks and Stratasys’ Origin printer. This partnership aims to scale up bioprinting solutions for the $3 billion breast implant market.
- Regenerative Potential: The 200cc implants, currently under pre-clinical study, are designed to promote natural breast tissue growth and biodegrade completely over time, offering a potential alternative to traditional silicone implants with the added benefit of not triggering an immune response.
- Promising Pre-Clinical Results: Early pre-clinical data shows that the implants support tissue regeneration and initial biodegradation without adverse reactions, indicating the implants’ safety and effectiveness. The first study results are expected in the first half of 2025.
——————————————————————————————————————————————————
CollPlant Biotechnologies and Stratasys Ltd. launched a pre-clinical study using 200cc regenerative implants, 3D-printed with CollPlant’s bioinks on a Stratasys Origin printer. The collaboration is focused on developing and scaling up bioprinting solutions for breast implants. The study will assess the implants’ ability to promote natural breast tissue growth and their potential for complete biodegradation over time.
Regenerative Breast Tissue Implants
CollPlant’s breast implants are designed to regenerate natural breast tissue without triggering an immune response and could serve as an alternative for reconstructive and aesthetic procedures in the $3 billion breast implant market.
“This pre-clinical study marks a significant step forward in our effort to provide patients with care using regenerative medicine instead of traditional implants,” says Stratasys CEO Yoav Zeif, PhD. “CollPlant’s work is truly inspiring, and our collaboration exemplifies how Stratasys partners with customers to push the timeline and the boundaries of innovation. Together, we are driven by a shared mission to challenge the status quo and find new ways to improve lives and advance healthcare.”
High-Resolution Regenerative Implants
CollPlant CEO Yehiel Tal also spoke out about the pre-clinical study, commenting: “We are extremely happy about the progress we’ve made with our breast implants program, and with Stratasys’ successful achievement to develop a printer that enables us to print a commercial-size implant with high resolution and optimal physical properties. The combined pioneering technologies of both companies is expected to streamline the development and production process so that we have the most efficient means to produce our regenerative breast implants.”
“We believe that our rhCollagen-based regenerative implant has the potential to overcome the challenges of existing breast procedures that use silicone implants or autologous fat transfer, thereby significantly improving patient outcomes,” Tal adds.
Since their collaboration began in April 2023, Stratasys has adapted the Origin printer to produce 200cc regenerative implants, which CollPlant has successfully 3D-printed. Initial study results are expected in the first half of 2025.
Earlier this year, CollPlant reported data from ongoing pre-clinical studies showing well-developed connective tissue and blood vessels forming within the implant. Tissue regeneration and initial biodegradation were observed, with the implant’s structure remaining intact. No adverse tissue reactions were detected, indicating the implant’s safety.
